Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.

ABSTRACT:

Background

The Japanese 'BALAD' model offers the first objective, biomarker-based, tool for assessment of prognosis in hepatocellular carcinoma, but relies on dichotomisation of the constituent data, has not been externally validated, and cannot be applied to the individual patients.

Methods

In this Japanese/UK collaboration, we replicated the original BALAD model on a UK cohort and then built a new model, BALAD-2, on the original raw Japanese data using variables in their continuous form. Regression analyses using flexible parametric models with fractional polynomials enabled fitting of appropriate baseline hazard functions and functional form of covariates. The resulting models were validated in the respective cohorts to measure the predictive performance.

Results

T

SUBMITTER: Fox R 

PROVIDER: S-EPMC3992496 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature